Contribution of homozygous and compound heterozygous missense mutations in VWA2 to Alzheimer’s disease

Alzheimer’s disease is the most frequent diagnosis of neurodegenerative dementia with early (≤65 years) and late (>65 years) onset ages in familial and sporadic patients. Causal mutations in 3 autosomal dominant Alzheimer genes, i.e. amyloid precursor protein (APP), presenilin 1 (PSEN1) and prese...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Neurobiology of aging 2021-03, Vol.99, p.100.e17-100.e23, Article 100
Hauptverfasser: Hoogmartens, Julie, Hens, Elisabeth, Engelborghs, Sebastiaan, Vandenberghe, Rik, De Deyn, Peter-P., Cacace, Rita, Van Broeckhoven, Christine, Cras, P., Goeman, J., Crols, R., De Bleecker, J.L., Van Langenhove, T., Sieben, A., Dermaut, B., Deryck, O., Bergmans, B., Versijpt, J.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Alzheimer’s disease is the most frequent diagnosis of neurodegenerative dementia with early (≤65 years) and late (>65 years) onset ages in familial and sporadic patients. Causal mutations in 3 autosomal dominant Alzheimer genes, i.e. amyloid precursor protein (APP), presenilin 1 (PSEN1) and presenilin 2 (PSEN2), explain only 5%–10% of early-onset patients leaving the majority of patients genetically unresolved. To discover potential missing genetics, we used whole genome sequencing data of 17 early-onset patients with well-documented clinical diagnosis of Alzheimer’s disease. In the discovery group, the mean onset age was 55.71 ± 6.83 years (range 37–65). Six patients had a brain autopsy and neuropathology confirmed Alzheimer’s disease. Analysis of the genetic data identified in one patient a homozygous p.V366M missense mutation in the Von Willebrand factor A domain containing 2 gene (VWA2). Resequencing of the VWA2 coding region in an Alzheimer's disease patient cohort from Flanders-Belgium (n = 1148), including 152 early and 996 late onset patients, identified additional homozygous and compound heterozygous missense mutations in 1 early and 3 late-onset patients. Allele-sharing analysis identified common haplotypes among the compound heterozygous VWA2 mutation carriers, suggesting shared ancestors. Overall, we identified 5 patient carriers of homozygous or compound heterozygous missense mutations (5/1165; 0.43 %), 2 in early (2/169; 1.18 %) and 3 in late-onset (3/996; 0.30 %) patients. The frequencies of the homozygous and compound heterozygous missense mutations in patients are higher than expected from the frequencies calculated based on their combined single alleles. None of the homozygous/compound heterozygous missense mutation carriers had a family history of autosomal dominant Alzheimer’s disease. Our findings suggest that homozygous and compound heterozygous missense mutations in VWA2 might contribute to the risk of Alzheimer’s disease in sporadic patients. •17 EOAD patients were selected for WGS analysis.•WGS data analysis identified the homozygous p.V366M in VWA2 in one patient.•Resequencing of VWA2 identified 4 additional homozygous/compound heterozygous missense mutations in AD patients.•Our findings suggest that homozygous and compound heterozygous missense mutations in VWA2 might contribute to AD.
ISSN:0197-4580
1558-1497
DOI:10.1016/j.neurobiolaging.2020.09.009